Equities analysts predict that TRACON Pharmaceuticals Inc (NASDAQ:TCON) will post ($1.57) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for TRACON Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.64) and the highest is ($1.50). TRACON Pharmaceuticals posted earnings per share of ($2.60) in the same quarter last year, which would suggest a positive year over year growth rate of 39.6%. The firm is expected to issue its next quarterly earnings results on Thursday, February 27th.
On average, analysts expect that TRACON Pharmaceuticals will report full-year earnings of ($7.75) per share for the current year, with EPS estimates ranging from ($7.89) to ($7.60). For the next year, analysts forecast that the business will report earnings of ($1.24) per share, with EPS estimates ranging from ($4.48) to $2.00. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover TRACON Pharmaceuticals.
TRACON Pharmaceuticals (NASDAQ:TCON) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.03.
Several equities research analysts have weighed in on TCON shares. Zacks Investment Research upgraded shares of TRACON Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 4th. HC Wainwright restated a “buy” rating and issued a $2.00 target price on shares of TRACON Pharmaceuticals in a research note on Thursday, November 7th.
TCON stock traded down $0.07 during mid-day trading on Thursday, reaching $3.12. The company had a trading volume of 29,200 shares, compared to its average volume of 33,685. The company has a market capitalization of $10.00 million, a PE ratio of -0.24 and a beta of 2.28. TRACON Pharmaceuticals has a 12 month low of $2.78 and a 12 month high of $17.30. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.58 and a quick ratio of 1.58. The firm has a 50 day moving average of $0.81 and a 200 day moving average of $0.64.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Susquehanna International Group LLP purchased a new position in shares of TRACON Pharmaceuticals in the second quarter worth $26,000. Wedbush Securities Inc. purchased a new position in shares of TRACON Pharmaceuticals in the second quarter worth $32,000. Finally, Renaissance Technologies LLC raised its holdings in shares of TRACON Pharmaceuticals by 17.5% in the second quarter. Renaissance Technologies LLC now owns 1,209,203 shares of the biopharmaceutical company’s stock worth $822,000 after buying an additional 179,718 shares during the last quarter. Institutional investors own 54.72% of the company’s stock.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD.
Further Reading: Convertible Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.